Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
GermanyIn short
Diagnosing uterine cancer typically begins when a woman notices unusual bleeding or other symptoms, prompting her to seek medical attention. Early detection is crucial, as most cases can be cured when found in the early stages, making awareness of warning signs and prompt medical evaluation essential for all women, especially those approaching or past menopause.
Any woman who experiences abnormal vaginal bleeding should consider seeking diagnostic evaluation for uterine cancer. This disease, which develops in the cells of the uterus, most commonly affects women who are going through or have completed menopause, the time when menstrual periods stop permanently. All women who still have a uterus remain at risk regardless of age, though the likelihood increases as they get older.
The most important warning sign that should prompt you to visit your doctor is irregular vaginal bleeding. If you have already gone through menopause, any amount of vaginal bleeding or spotting is considered abnormal and needs immediate attention. Even a slight amount matters and should not be ignored. For women who have not yet reached menopause, bleeding between regular periods, unusually heavy or prolonged bleeding, or bleeding that occurs more frequently than normal are all reasons to seek medical evaluation.
Beyond bleeding, other symptoms warrant diagnostic testing. These include unusual vaginal discharge that is thin, white, or clear, especially after menopause. Pain in the pelvic area, difficulty or discomfort during urination, frequent need to urinate, pain during sexual intercourse, or feeling a lump or mass in the vaginal area are all indicators that something may be wrong and require investigation.
Women with certain risk factors should be especially vigilant about symptoms and may benefit from discussing screening with their healthcare provider. Risk factors include having obesity, diabetes, taking estrogen-only hormone replacement therapy after menopause, never having been pregnant, starting periods at an early age or experiencing menopause at a later age, and having a family history of endometrial cancer. Certain inherited conditions like Lynch syndrome also increase risk.
When you visit your doctor with symptoms that could indicate uterine cancer, the diagnostic process typically begins with a thorough discussion of your medical history and a physical examination. Your doctor will want to know about your symptoms, when they started, your menstrual history, any medications you take, and your family health background. This conversation helps your healthcare provider understand your individual situation and risk factors.
A pelvic exam is usually the first physical test performed. During this examination, your doctor inspects the external genital area and then inserts two gloved fingers into your vagina while pressing on your abdomen with the other hand. This allows them to feel the size and shape of your uterus and ovaries and check for any abnormalities. A device called a speculum is inserted into the vagina to hold it open so the doctor can visually examine the vaginal canal and cervix. While a pelvic exam is important, it cannot definitively diagnose uterine cancer on its own.
One of the most common imaging tests used to evaluate the uterus is a transvaginal ultrasound. This test uses sound waves to create images of the tissues inside your uterus and pelvic area. During the procedure, a wand-like device called a transducer is gently inserted into your vagina. The transducer emits sound waves that bounce off internal organs and create pictures on a screen. This test allows your doctor to see the thickness of the endometrium, which is the inner lining of the uterus, and identify any unusual growths or masses. It's a painless procedure that provides valuable information without using radiation.
To confirm whether cancer cells are present, your doctor needs to examine actual tissue from your uterus under a microscope. An endometrial biopsy is a procedure where a small sample of tissue is removed from the lining of your uterus. This is often done in the doctor's office without requiring anesthesia. A thin tube is inserted through the cervix into the uterus, and a small amount of endometrial tissue is collected. A specialist called a pathologist then examines this tissue sample under a microscope to look for cancer cells or precancerous changes.
If the endometrial biopsy doesn't provide enough tissue or if results are unclear, your doctor may recommend a dilation and curettage, commonly called a D&C. This is a more thorough procedure that's usually performed in an operating room with anesthesia. The cervix is gently opened (dilated), and a spoon-shaped or loop-shaped instrument called a curette is inserted into the uterus to scrape tissue from the endometrial lining. This provides a larger tissue sample for the pathologist to examine, which can lead to a more definitive diagnosis.
A hysteroscopy allows your doctor to directly see inside your uterus. During this procedure, a thin tube called a hysteroscope, which has a light and camera attached to it, is inserted through the vagina and cervix into the uterus. The camera sends images to a screen, allowing your doctor to examine the endometrium visually and identify any abnormal areas. If suspicious tissue is spotted during hysteroscopy, your doctor can take a biopsy sample through the hysteroscope for testing. This procedure may be done in the office or hospital, sometimes with light sedation for comfort.
If uterine cancer is confirmed through tissue sampling, your doctor will likely order additional imaging tests to determine whether the cancer has spread beyond the uterus. These staging tests help guide treatment decisions. Common imaging tests include computed tomography (CT) scans, which use X-rays to create detailed cross-sectional images of your body, and magnetic resonance imaging (MRI) scans, which use magnets and radio waves to produce detailed pictures of soft tissues. Chest X-rays may be performed to check whether cancer has spread to the lungs.
Blood tests are typically part of the diagnostic workup as well. While no blood test can diagnose uterine cancer directly, blood work helps assess your overall health and organ function before treatment begins. Some patients may undergo genetic testing or molecular testing of their tumor tissue to identify specific characteristics that could influence treatment choices.
Clinical trials test new treatments for uterine cancer and may offer access to innovative therapies not yet widely available. To participate in a clinical trial, patients must meet specific criteria established by researchers. Diagnostic testing plays a crucial role in determining whether someone qualifies for a particular trial.
The first requirement for most uterine cancer clinical trials is confirmation of the diagnosis through tissue biopsy. The pathology report documenting cancer cells in endometrial tissue is essential. Beyond basic diagnosis, many trials require knowledge of the cancer's stage, which indicates how far the disease has spread. Staging typically requires surgical exploration or advanced imaging studies to assess whether cancer is confined to the uterus or has extended to nearby organs, lymph nodes, or distant sites.
The grade of the cancer is another important factor. Grade describes how abnormal the cancer cells look under a microscope and how quickly they're likely to grow. High-grade cancers look very different from normal cells and tend to grow faster, while low-grade cancers more closely resemble normal tissue. Pathologists determine grade by examining biopsy samples, and this information often influences trial eligibility.
Many modern clinical trials require molecular or genetic testing of tumor tissue. Researchers may look for specific gene mutations, protein markers, or molecular characteristics that make certain treatments more likely to work. For example, some trials testing immunotherapy drugs require testing tumor tissue for specific proteins or genetic features that predict response to these medications. Testing might examine whether tumor cells have certain checkpoint proteins or genetic instabilities that immunotherapy can target.
Patients interested in clinical trials typically undergo comprehensive health assessments to ensure they're healthy enough to participate safely. This includes blood tests to check organ function, particularly the kidneys, liver, and bone marrow. Heart function may be evaluated with an electrocardiogram or echocardiogram. Performance status assessments measure how well you can carry out daily activities, as many trials require participants to have reasonable functional ability.
Previous treatment history also matters for trial qualification. Some trials specifically seek patients who have already tried standard treatments, while others enroll only those who haven't yet received therapy. Documentation of all prior treatments, including surgery, radiation, chemotherapy, or hormone therapy, becomes part of the screening process for clinical trial participation.
Imaging requirements for clinical trials are often more extensive than for standard care. Baseline scans document the exact size and location of all cancer deposits before treatment begins. These images serve as comparison points to measure whether experimental treatments are working. Trials may require specific types of imaging, such as PET scans or specialized MRI sequences, performed according to standardized protocols to ensure consistent measurements across all participants.
Some trials investigating new diagnostic methods or screening approaches may have different requirements. These studies might enroll women at high risk for uterine cancer who haven't yet been diagnosed, testing whether new techniques can detect cancer earlier or more accurately than current methods. Participation in such trials typically requires documentation of risk factors and may involve novel imaging or biomarker testing not yet part of routine care.
The outlook for women diagnosed with uterine cancer varies depending on several factors. The most important factor affecting prognosis is the stage at which cancer is discovered. Early-stage uterine cancer that is confined to the uterus has an excellent prognosis and can often be cured with treatment, particularly surgery. When endometrial cancer is detected early, which happens frequently because the disease typically causes noticeable symptoms like abnormal bleeding, the chances of successful treatment are very good.
The type of uterine cancer also influences prognosis. Endometrial carcinoma, which makes up about 95% of uterine cancer cases, generally has a better outlook than uterine sarcoma. Uterine sarcoma is rare but tends to be more aggressive and harder to treat. Within endometrial cancer itself, different subtypes exist with varying prognoses. Some molecular and cellular characteristics of the tumor affect how it responds to treatment and how likely it is to spread.
The grade of the cancer plays a role in determining outcomes. High-grade cancers, which look very abnormal under the microscope and grow rapidly, are more likely to spread and may require more aggressive treatment than low-grade cancers. A woman's overall health, age, and any other medical conditions she has also influence prognosis, as these factors affect her ability to tolerate treatment and recover.
For women with advanced-stage disease where cancer has spread beyond the uterus to other organs, the prognosis is more challenging. However, even in these situations, treatment can often control the disease, relieve symptoms, and extend survival. New treatment options, including immunotherapy and targeted therapies, are providing hope for patients with advanced or recurrent disease who previously had limited options.
Survival rates for uterine cancer depend heavily on the stage at diagnosis. The majority of women with endometrial cancer are diagnosed at an early stage because symptoms like abnormal bleeding typically prompt medical attention before the cancer spreads extensively. This early detection contributes to relatively favorable survival statistics compared to some other cancers.
Overall, approximately 3% of women will receive a diagnosis of uterine cancer at some point in their lives. About 65,000 women in the United States are diagnosed with the disease each year. While uterine cancer is the most common gynecologic cancer affecting the female reproductive system, many cases are successfully treated when caught early.
For women diagnosed with stage I uterine cancer, where the disease remains confined to the uterus, the prognosis is excellent. For stage II disease that has spread to the cervix, outcomes remain quite positive. Stages III and IV, where cancer has extended to nearby structures, lymph nodes, or distant organs, present more challenges, though treatment can still be effective in many cases.
It's important to understand that survival statistics are based on large groups of people and represent averages. Individual outcomes can vary significantly based on personal factors, the specific characteristics of the cancer, and the treatments received. No statistic can predict exactly what will happen to any individual patient. Advances in treatment continue to improve outcomes, meaning that current survival rates may underestimate the effectiveness of newer therapies available today.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
